Only about a month after entering the nasal delivery device market, Bespak has announced a second contract for development of an intranasal device. The company says that "a major global manufacturer of generic medicines" has awarded Bespak a contract for both development of its Unidose nasal drug delivery device for an undisclosed application and for manufacturing and … [Read more...] about Second nasal delivery device contract for Bespak
News
Teva offering assistance to Primatene Mist users
Teva Respiratory has announced that it will provide assistance to patients affected by the impending phase out of the OTC Primatene Mist epinephrine inhaler. In addition to providing educational resources, the company says that it will offer financial assistance programs and samples of its ProAir HFA albuterol and QVar HFA beclamethasone metered dose inhalers. Teva … [Read more...] about Teva offering assistance to Primatene Mist users
No safety problems for Nanotherapeutics’ nasal dry powder vaccine in Phase 1 trial
A Phase 1 clinical trial of a novel dry powder intranasal vaccine for prevention of the H5N1 influenza strain demonstrated that the product was well tolerated, and no serious adverse events occurred, according to developer Nanotherapeutics. the GelVac nasal dry powder H5N1 vaccine is delivered by a disposable single-use positive pressure intranasal inhaler that uses … [Read more...] about No safety problems for Nanotherapeutics’ nasal dry powder vaccine in Phase 1 trial
PPD agrees to be acquired for $3.9 billion
The board of directors of contract research organization PPD has approved a $3.9 billion all cash deal which will take the company private after its acquisition by the Carlyle Group and Hellman & Friedman. PPD offers formulation development and analytical services for a wide variety of OINDPs, including DPIs, MDIs, inhalation solutions, and nasal aerosols. The deal, … [Read more...] about PPD agrees to be acquired for $3.9 billion
British Pharmacopoeia adds working party for inhaled products, seeks input
According to the British Pharmacopoeia website: "The British Pharmacopoeia Commission has recently endorsed the formation of a new Working Party for Inhaled Products (IP). The remit of the Working Party will be to review the current published monographs for Inhaled Products and associated General Monographs and Supplementary Chapters." "Stakeholders are invited … [Read more...] about British Pharmacopoeia adds working party for inhaled products, seeks input
Frank Morich named new CEO of Nycomed as Takeda completes acquisition
As Nycomed officially becomes a wholly owned subsidiary of Takeda Pharmaceutical Company, Takeda has named Frank Morich as the new Nycomed CEO. Morich will also continue in his current position as Executive VP (EVP) of International Operations (Americas/Europe) for Takeda Pharmaceuticals International. “I look forward to bringing Takeda and Nycomed together to … [Read more...] about Frank Morich named new CEO of Nycomed as Takeda completes acquisition
Effort to study COPD prevalence in Sub-Saharan African launched
The International Primary Care Respiratory Group (IPCRG) has launched a petition in support of its Fresh Air Uganda study in response to what it says is a growing threat in the region, with COPD expected to surpass HIV/AIDs as the third-leading cause of death in Africa by 2025. The epidemiological study in rural Uganda will involve 600 people over the age of 30, … [Read more...] about Effort to study COPD prevalence in Sub-Saharan African launched
Manufacturer of MaxAir Autohaler purchased by dermatology-focused company
Graceway Pharmaceuticals, which manufactures the MaxAir Autohaler pirbuterol acetate MDI, one of the last remaining CFC-propelled metered dose inhalers, has agreed to sell all of its assest to Galderma, a " company focused exclusively on meeting the needs of dermatology patients and physicians." The MaxAir inhaler is scheduled for phase out two years from now, with a … [Read more...] about Manufacturer of MaxAir Autohaler purchased by dermatology-focused company
Pulmatrix presents data from preclinical studies of its inhaled calcium salts
Massachusetts biotech company Pulmatrix presented data from two studies of its Pulmatrix presents data from preclinical studies of its lead product, PUR118, an inhaled cationic airway lining modulator (iCALM) for the treatment of respiratory diseases in oral and poster sessions at the 2011 European Respiratory Society (ERS) conference. The data show that PUR118 … [Read more...] about Pulmatrix presents data from preclinical studies of its inhaled calcium salts
Novartis has filed MAA for Seebri Breezhaler in Europe
Novartis has filed a marketing authorization application (MAA) with the European Medicines Agency (EMA) for its NVA237 glycopyrronium bromide dry powder inhaler, which will be called the Seebri Breezhaler. The MAA once-daily long-acting antimuscarinic (LAMA) triggered a $5 million milestone payment to Sosei, which co-developed the product with Vectura and licensed it … [Read more...] about Novartis has filed MAA for Seebri Breezhaler in Europe